Monitor for the first prospectus supplement, which will reveal the specific terms of the offering. The offering is likely to be dilutive, and given the company's cash burn and need to fund a large Phase 3 trial, a near-term capital raise is probable. The stock price may react negatively to the announcement of any equity offering.
Price Chart
Executive Summary
Minerva Neurosciences filed an S-3 shelf registration statement allowing it to raise up to $200 million through future offerings of common stock, preferred stock, debt securities, or warrants. This filing signals a potential capital raise, likely to fund its Phase 3 confirmatory trial for roluperidone and other corporate purposes, following a recent $80 million private placement. The market cap is $344 million, making the offering size significant relative to the company's size.
Key Financial Metrics
Key Facts
- Minerva Neurosciences (NERV) filed an S-3 shelf registration for up to $200 million in securities.
- The company recently completed a $80 million private placement of preferred stock and warrants on October 23, 2025.
- As of September 30, 2025, the company had $12.4 million in cash and an accumulated deficit of $405.1 million.
- The company's lead drug, roluperidone, received a Complete Response Letter (CRL) from the FDA in February 2024, requiring an additional Phase 3 trial.
- The company's market capitalization is $344 million, meaning the $200 million offering could result in significant dilution.
Financial Impact
The $200 million offering could result in up to 58% dilution of the current market cap. The company has a history of raising capital through dilutive private placements, as seen with the recent $80 million raise.
Risk Factors
- Significant shareholder dilution from a potential equity offering.
- The company may not be able to raise capital on favorable terms, or at all.
- Failure of the roluperidone Phase 3 confirmatory trial would severely impact the company's prospects.
- The company has a history of operating losses and may need to raise additional capital beyond this shelf offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-101196 |
| Document: d71904dex46.htm | 0001193125-26-101196 |
| CONTEXT: 10-Q (2025-11-05) | 0001193125-25-265685 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 8-K | $3.92 | awaiting T+60 | — | $2.23 (−42.98%) |
Aug 7, 2026 11w ago | 8-K | $4.27 | awaiting T+60 | — | $2.23 (−47.66%) |
May 27, 2026 21w ago | 8-K | $5.00 $4.84 | ▲ +3.20% | ▲ +4.93% | $2.23 (+55.30%) |
May 5, 2026 25w ago | 8-K | $6.25 $4.02 | ▼ −35.68% | ▼ −38.42% | $2.23 (−64.24%) |
Apr 23, 2026 26w ago | DEFA14A | $6.83 $4.37 | ▼ −36.02% | ▼ −41.04% | $2.23 (−67.28%) |
Mar 25, 2026 30w ago | Press Release | $6.14 $4.66 | ▼ −24.10% | ▼ −38.05% | $2.23 (−63.60%) |
Mar 20, 2026 31w ago | EFFECT | $7.54 $4.39 | ▼ −41.78% | ▼ −56.20% | $2.23 (−70.36%) |
Mar 11, 2026 32w ago | S-3 | $7.30 $4.68 | ▲ +35.89% | ▲ +47.41% | $2.23 (+69.38%) |
Mar 11, 2026 32w ago | Press Release | $7.30 $4.68 | ▼ −35.89% | ▼ −47.41% | $2.23 (−69.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers